ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
류마티스성 심질환 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년에는 연평균 6.0%의 성장률로 34억 4,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 예방 검진 프로그램 채택 증가, 조기 발견에 대한 인식 증가, 개발도상국의 헬스케어 투자 증가, 원격 진단을 위한 원격의료의 확대, 질병 예방에 대한 정부의 노력 등에 기인할 것으로 보입니다. 예측 기간 동안 예상되는 세계 동향으로는 진단을 위한 AI 활용 확대, 심초음파 검사 기반 스크리닝 확대, 모바일 헬스 솔루션의 통합, 새로운 항염증 치료법 개발, 세계 질병 퇴치를 위한 공동 연구 등이 있습니다.
연쇄상 구균 감염의 유병률 증가는 향후 류마티스성 심질환 시장의 성장을 견인할 것으로 예상됩니다. 연쇄상구균 감염은 화농성 연쇄상구균(A군 연쇄상구균)에 의한 세균 감염으로 인후염, 통증, 발열, 림프절 부종, 연하곤란을 유발하는 질환입니다. 항생제 내성균의 증가로 인해 연쇄상구균 감염증의 효과적인 치료가 어려워지고 있으며, 이로 인해 유병기간이 길어지고 지역사회 감염률이 높아지고 있습니다. 류마티스성 심질환은 연쇄상구균 감염의 미치료 또는 재발로 인한 장기적인 합병증으로 발병하여 심각한 심장질환을 예방하기 위한 연쇄상구균 감염의 조기 진단 및 치료의 중요성을 강조하고 있습니다. 예를 들어, 2023년 4월 미국 질병통제예방센터(CDC)는 연쇄상구균 감염이 65세 미만의 연간 외래 환자 중 약 520만 명이 연쇄상구균 감염을 앓고 있다고 보고했습니다. 이로 인해 매년 280만 건의 항생제 처방이 이루어지고 있습니다. 따라서 연쇄상 구균 감염의 증가는 류마티스성 심질환 시장의 성장에 기여하고 있습니다.
류마티스성 심질환 시장의 주요 업체들은 혁신적인 치료법과 진단 솔루션을 개발하기 위해 전략적 파트너십을 채택하고 있습니다. 이러한 파트너십은 연구 촉진, 진단 및 치료 기술 향상, 시장 범위 확대, 제품화 가속화 등을 위해 자원과 전문 지식을 결합하는 것입니다. 예를 들어, 2023년 7월 스위스에 본부를 둔 NGO인 세계심장연맹(WHF)은 네덜란드에 본부를 둔 비영리단체인 필립스 재단과 파트너십을 맺고 아시아태평양(APAC) 지역에서 류마티스성 심질환(RHD)에 대한 인식 제고, 의료 교육 및 조기 발견을 위해 협력하기로 했습니다. 필리핀에서 시작된 이 이니셔티브는 의료 시설에 숙련된 전문가와 첨단 진단 도구를 제공함으로써 위험에 처한 50만 명 이상의 필리핀 어린이들의 의료 접근성을 개선하는 것을 목표로 하고 있습니다. 이번 협력은 의료 인프라를 강화하고 RHD 환자에게 적시에 개입할 수 있도록 하기 위한 공동의 노력을 강조하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 류마티스성 심질환 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 류마티스성 심질환 시장 : 성장률 분석
세계의 류마티스성 심질환 시장 실적 : 규모와 성장, 2019-2024
세계의 류마티스성 심질환 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 류마티스성 심질환 전체 시장(TAM)
제6장 시장 세분화
세계의 류마티스성 심질환 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
밸브
심근염
심막염
세계의 류마티스성 심질환 시장 : 연령층별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
소아(0-14세)
청소년기(15-24세)
성인(25-64세)
노인(65세 이상)
세계의 류마티스성 심질환 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
진단 센터
연구 센터
세계의 류마티스성 심질환 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
소매 약국
온라인 약국
직접 판매
세계의 류마티스성 심질환 시장, 밸브 하위 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
승모판 질환
대동맥판 질환
삼첨판 질환
폐동맥판 질환
세계의 류마티스성 심질환 시장 심근염 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
급성 심근염
만성 심근염
극증 심근염
세계의 류마티스성 심질환 시장, 심막염 종류별 하위 세분화, 실적과 예측, 2019-2024, 2024-2029F, 2034F
급성 심막염
만성 심막염
수축성 심막염
삼출성 심막염
제7장 지역별·국가별 분석
세계의 류마티스성 심질환 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 류마티스성 심질환 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
류마티스성 심질환 시장 : 경쟁 구도
류마티스성 심질환 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
Bayer AG Overview, Products and Services, Strategy and Financial Analysis
Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 주요 기업과 혁신적 기업
Novartis AG
Abbott Laboratories
GlaxoSmithKline plc(GSK)
Medtronic plc
Siemens Healthineers AG
Fresenius Medical Care AG & Co. KGaA
Becton Dickinson and Company(BD)
GE HealthCare Technologies Inc.
Mayo Clinic
Boston Scientific Corporation
Johns Hopkins Medicine
Terumo Corporation
The Mount Sinai Health System Inc.
Apollo Hospitals Enterprise Limited
Fortis Healthcare Limited
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병
제34장 최근의 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
류마티스성 심질환 시장 2029 : 새로운 기회를 제공하는 국가
류마티스성 심질환 시장 2029 : 새로운 기회를 제공하는 부문
류마티스성 심질환 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁 전략
제36장 부록
ksm
영문 목차
영문목차
Rheumatic heart disease (RHD) is a chronic condition caused by permanent damage to the heart valves due to rheumatic fever, an inflammatory disease that results from untreated or inadequately treated streptococcal throat infections. The immune response triggered by the infection causes inflammation and scarring of the heart valves, impairing their function and potentially leading to heart failure, arrhythmias, or other complications.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The primary types of rheumatic heart disease include valve-related disease, myocarditis, and pericarditis. Valve-related rheumatic heart disease occurs when rheumatic fever damages the heart valves, leading to impaired blood flow and complications such as stenosis or regurgitation. Affected age groups include pediatric, adolescent, adult, and geriatric populations. Rheumatic heart disease is treated and managed across various healthcare settings, such as hospitals, diagnostic centers, and research institutions. The distribution channels for related medications include hospital pharmacies, retail pharmacies, online pharmacies, and direct sales.
The rheumatic heart disease market research report is one of a series of new reports from The Business Research Company that provides rheumatic heart disease market statistics, including the rheumatic heart disease industry global market size, regional shares, competitors with the rheumatic heart disease market share, detailed rheumatic heart disease market segments, market trends, and opportunities, and any further data you may need to thrive in the rheumatic heart disease industry. This rheumatic heart disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The rheumatic heart disease market size has grown strongly in recent years. It will grow from$2.56 billion in 2024 to $2.72 billion in 2025 at a compound annual growth rate (CAGR) of 6.3%. The growth during the historic period can be attributed to the prevalence of untreated strep infections, limited access to healthcare in low-income regions, a lack of awareness about rheumatic heart disease, delayed diagnosis and treatment, and insufficient vaccination programs.
The rheumatic heart disease market size is expected to see strong growth in the next few years. It will grow to$3.44 billion in 2029 at a compound annual growth rate (CAGR) of 6.0%. The growth during the forecast period can be attributed to the increasing adoption of preventive screening programs, growing awareness about early detection, rising healthcare investments in developing regions, the expansion of telemedicine for remote diagnosis, and government initiatives for disease prevention. Key trends anticipated in the forecast period include the growing use of AI in diagnostics, the expansion of echocardiography-based screening, the integration of mobile health solutions, the development of novel anti-inflammatory therapies, and collaborations aimed at global disease eradication.
The growing prevalence of strep throat is expected to drive the growth of the rheumatic heart disease market in the future. Strep throat is a bacterial infection caused by Streptococcus pyogenes (group A streptococcus), leading to throat inflammation, pain, fever, swollen lymph nodes, and difficulty swallowing. The rise in antibiotic resistance is making streptococcal infections harder to treat effectively, resulting in prolonged illnesses and higher transmission rates in communities. Rheumatic heart disease develops as a long-term complication of untreated or recurrent strep throat infections, emphasizing the importance of early diagnosis and treatment of streptococcal infections to prevent severe heart damage. For example, in April 2023, the Centers for Disease Control and Prevention (CDC), a US-based government agency, reported that strep throat accounts for approximately 5.2 million outpatient visits annually among individuals under 65 years old. These visits lead to 2.8 million antibiotic prescriptions each year. Therefore, the increasing prevalence of strep throat is contributing to the growth of the rheumatic heart disease market.
Key players in the rheumatic heart disease market are adopting strategic partnerships to develop innovative treatments and diagnostic solutions. These partnerships combine resources and expertise to advance research, improve diagnostic and therapeutic technologies, expand market reach, and expedite commercialization. For instance, in July 2023, the World Heart Federation (WHF), a Switzerland-based NGO, joined forces with the Philips Foundation, a Netherlands-based nonprofit, to increase awareness, medical training, and early detection of rheumatic heart disease (RHD) in the Asia-Pacific (APAC) region. Launched in the Philippines, this initiative aims to improve healthcare access for over half a million Filipino children at risk by equipping healthcare facilities with trained professionals and advanced diagnostic tools. This collaboration highlights a shared commitment to strengthening healthcare infrastructure and ensuring timely intervention for RHD patients.
In February 2025, Light AI Inc., a healthcare technology company based in Canada, partnered with MrBeast Industries to support global health initiatives. The collaboration focuses on providing AI-powered Strep A tests across Africa, enabling early detection and prevention of the disease to reduce the risk of complications such as rheumatic heart disease. MrBeast Industries is a US-based media and entertainment company known for its digital content creation.
Major players in the rheumatic heart disease market are Pfizer Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, Novartis AG, Abbott Laboratories, GlaxoSmithKline plc (GSK), Medtronic plc, Siemens Healthineers AG, Fresenius Medical Care AG & Co. KGaA, Becton Dickinson and Company (BD), GE HealthCare Technologies Inc., Mayo Clinic, Boston Scientific Corporation, Johns Hopkins Medicine, Terumo Corporation, The Mount Sinai Health System Inc., Apollo Hospitals Enterprise Limited, Fortis Healthcare Limited, and Medanta.
North America was the largest region in the rheumatic heart disease market in 2024. The regions covered in rheumatic heart disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the rheumatic heart disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The rheumatic heart disease market consists of revenues earned by entities by providing services such as surgical treatments, diagnostic tests, preventive care services, and pediatric care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The rheumatic heart disease market also includes sales of antibiotics, anti-inflammatory medications, diuretics, beta-blockers, and ACE inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Rheumatic Heart Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on rheumatic heart disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for rheumatic heart disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The rheumatic heart disease market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Valve; Myocarditis; Pericarditis
2) By Age Group: Pediatric; Adolescent; Adult; Geriatric
3) By Application: Hospital; Diagnostic Centre; Research Centre
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Direct Sales
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Rheumatic Heart Disease Market Characteristics
3. Rheumatic Heart Disease Market Trends And Strategies
4. Rheumatic Heart Disease Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Rheumatic Heart Disease Growth Analysis And Strategic Analysis Framework
5.1. Global Rheumatic Heart Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Rheumatic Heart Disease Market Growth Rate Analysis
5.4. Global Rheumatic Heart Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Rheumatic Heart Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Rheumatic Heart Disease Total Addressable Market (TAM)
6. Rheumatic Heart Disease Market Segmentation
6.1. Global Rheumatic Heart Disease Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Valve
Myocarditis
Pericarditis
6.2. Global Rheumatic Heart Disease Market, Segmentation By Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pediatric (0-14 Years)
Adolescent (15-24 Years)
Adult (25-64 Years)
Geriatric (65 Years And Above)
6.3. Global Rheumatic Heart Disease Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital
Diagnostic Centre
Research Centre
6.4. Global Rheumatic Heart Disease Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Direct Sales
6.5. Global Rheumatic Heart Disease Market, Sub-Segmentation Of Valve, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Mitral Valve Disease
Aortic Valve Disease
Tricuspid Valve Disease
Pulmonary Valve Disease
6.6. Global Rheumatic Heart Disease Market, Sub-Segmentation Of Myocarditis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Myocarditis
Chronic Myocarditis
Fulminant Myocarditis
6.7. Global Rheumatic Heart Disease Market, Sub-Segmentation Of Pericarditis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Acute Pericarditis
Chronic Pericarditis
Constrictive Pericarditis
Effusive Pericarditis
7. Rheumatic Heart Disease Market Regional And Country Analysis
7.1. Global Rheumatic Heart Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Rheumatic Heart Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
